Roche says Ocrevus drug reduces need for walking aids for MS patients

There was a 35 per cent reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and a half years of taking Ocrevus
Read Article

Roche said its Ocrevus treatment showed fewer patients with relapsing multiple sclerosis needed walking aids, the company said today.

There was a 35 per cent reduction in the need for a walking aid in patients with relapsing multiple sclerosis (MS) after seven and a half years of taking Ocrevus, the company said. There was also a 29 per cent reduction in the 48-week progression in primary progressive MS after eight years after starting taking the drug, it added.

Ocrevus treatmentRoche
Comments (0)
Add Comment